Patt, Y.Z., Hassan, M.M., Lozano, R.D., Waugh, K.A., Hoque, A.M., Frome, A.I., Lahoti, S., Ellis, L., Vauthey, J.N., Curley, S.A., Schnirer, I.I. and Raijman, I. (2001) Phase II Trial of Cisplatin, Interferon Alpha-2 b, Doxorubicin and 5-Fluorouracil for Biliary Tract Cancer. Clinical Cancer Research, 7, 3375-3380.

has been cited by the following article:

• TITLE: Role of Combination Chemotherapy with 5-Fluorouracil, Cisplatin and Paclitaxel for Advanced Gall Bladder Cancer

  AUTHORS: Mumtaz Ahmad Ansari, Satyendra K. Tiwary, Uday Pratap Shahi, Vijay K. Shukla

  KEYWORDS: Advanced Gallbladder Carcinoma; Combination Chemotherapy; Prognosis

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.3, March 19, 2014

  ABSTRACT: Aim: The prognosis for patients with advanced Gallbladder carcinoma is poor. Due to unresectability and relatively ineffective chemotherapy available, a need exists for effective chemotherapeutic regimen. The aim of this study was to determine the efficacy and safety profile of 5-fluorouracil, cisplatin and paclitaxel in patients with advanced Gallbladder cancer. Material and Methods: From January 2002 to July 2004, 40 patients of advanced carcinoma Gallbladder received 5-fluorouracil, cisplatin and paclitaxel. On day 1, paclitaxel was given (150 mg/m2), cisplatin was given on day 2 (50 mg/m2) and 5-fluorouracil was given from day 1 to day 3 (500 mg/m2). This cycle was repeated every three weeks and patient assessment was done. Results: Forty patients were enrolled in this study. Thirty-five were assessed for response. Five patients were lost in follow up. There were thirty females and ten males. A median of three cycles of treatment (range one to seven) was administered. Two patients achieved complete response and eleven had partial responses giving an overall response rate of 32.5% in the intention-to-treat population (95% confidence interval 11.1% to 46.5%). The median response duration was 5.3 months. The median time to progression and overall survival was 4.1 months and 11.2 months, respectively. The most common grade 3 adverse effects were neutropenia (30%), nausea (20%), vomiting (15%), diarrhea (10%), stomatitis (5%), and peripheral neuropathy (5%). Only one case had febrile neutropenia. There was no treatment related death. Conclusions: The combination of 5-fluorouracil, cisplatin and paclitaxel has promising anti-tumor activity and is well tolerated in patients with advanced and metastatic Gallbladder cancer.